Salt Lake City, UT Clinical Trials Report — July 2026

Salt Lake City participants should act promptly if they match a study nearing its enrollment deadline: 46 recruiting trials are expected to close within the next 90 days, including 3 that accept healthy volunteers. The city has 903 recruiting trials across 265 research facilities, so people who do not qualify for one study may still have other local options.

July brought 18 new trials, exactly matching the May total. New openings span drug, behavioral, biological, device, and other study types, with drug trials leading at 7. The University of Utah is the most active new-trial sponsor, responsible for 7 openings, while industry sponsors account for 8 and other organizations, including academic institutions, account for 10.

Closing windows include heart, lung, cancer, and orthopedic conditions

Enrollment can end before a projected closing date if a study reaches its target, making early contact especially important for people with the conditions listed below:

• Hypertension (2 trials)
• ARID1A gene mutation (1 trial)
• Atrial fibrillation (1 trial)
• Total hip replacement (1 trial)
• Asthma (1 trial)
• Atrial arrhythmia (1 trial)
• Knee replacement (1 trial)
• Atrial tachycardia (1 trial)
• B-cell acute lymphoblastic leukemia (1 trial)
• Bleeding (1 trial)

Only three of the closing-soon studies accept healthy volunteers. Healthy participants have more choice across the city overall: 80 healthy-volunteer trials are currently recruiting in Salt Lake City. Eligibility may still depend on age, medications, medical history, laboratory results, and the time required for visits.

Major new Phase 2 and Phase 3 studies open locally

Several large sponsored studies make July’s pipeline particularly notable. These include late-stage cancer research from Bristol-Myers Squibb and AbbVie, as well as a Phase 2 metabolic study involving semaglutide:

• Bristol-Myers Squibb is sponsoring NCT07680790, the Phase 3 IZABRIGHT-Lung02 study. It compares izalontamab brengitecan combined with osimertinib against osimertinib alone or osimertinib with platinum-based chemotherapy in adults with previously untreated, locally advanced or metastatic EGFR-mutant non-small cell lung cancer. Planned enrollment is 850 participants.
• AbbVie is sponsoring NCT07728188, a Phase 3 study comparing injected etentamig plus oral pomalidomide with standard therapies for adults with relapsed or refractory multiple myeloma. The study plans to enroll 520 participants.
• Antag Therapeutics is sponsoring NCT07724340, a Phase 2 study of AT673 given with semaglutide in adults with overweight or obesity and type 2 diabetes. Researchers will assess whether the combination improves weight loss and blood-sugar control. Planned enrollment is 150 participants.
• University of Utah is sponsoring NCT07716280, a study of digital-health implementation strategies designed to improve lung cancer screening in safety-net clinics. The project plans to include 800 participants across three Utah safety-net healthcare systems.
• Alexion Pharmaceuticals, Inc. is sponsoring NCT07732361, a real-world-data study examining outcomes in children and adults who develop thrombotic microangiopathy after hematopoietic stem-cell transplantation. Planned enrollment is 307 participants.

Other new July conditions include allergic reaction, aphasia and Broca’s aphasia, atrophy, cancer, cancer survivorship, chemotherapy-induced peripheral neuropathy, and COVID-19 vaccines. The month’s new-study mix also includes 4 behavioral trials, 3 studies classified as other, 2 biological studies, and 2 device studies.

University of Utah sites provide the city’s largest research network

The University of Utah and its affiliated facilities dominate Salt Lake City’s local trial access. The main University of Utah location lists 196 recruiting trials, while Huntsman Cancer Institute and University of Utah lists 83. Primary Children’s Hospital has 63, and Huntsman Cancer Institute lists 62. This concentration gives patients access to oncology, children’s research, metabolic studies, neurology, behavioral research, and other specialties through a closely connected academic health system.

• University of Utah (196 trials)
• Huntsman Cancer Institute/University of Utah (83 trials)
• Primary Children’s Hospital (63 trials)
• Huntsman Cancer Institute (62 trials)
• Huntsman Cancer Institute, University of Utah (35 trials)
• University of Utah Health (22 trials)
• University of Utah Hospital (18 trials)
• Research Site (18 trials)
• University of Utah Sugarhouse Health Center (17 trials)
• Huntsman Cancer Institute at University of Utah (16 trials)
• LDS Hospital (15 trials)
• VA Salt Lake City Health Care System (13 trials)

Who may find an opening this month?

Of the 18 new July trials, 6 accept healthy volunteers. Three include children, none are limited to women, and none are limited to men. Older adults are included in 15 new studies, broadening opportunities for people considering research later in life. University of Utah’s strong sponsorship presence also means that many openings may be connected to local academic clinics rather than commercial research centers.

People with EGFR-mutant lung cancer, relapsed or refractory multiple myeloma, type 2 diabetes with overweight or obesity, transplant-related thrombotic microangiopathy, or lung-screening implementation interests should review the new studies first. Healthy volunteers should focus on the six new eligible studies and the broader pool of 80 recruiting trials, while contacting sites soon for the three closing studies that accept healthy participants.

Other Utah cities offer additional choices

Participants able to travel can also search nearby Utah locations. Recruiting trials are listed in Bountiful, Murray, Provo, St. George, and West Valley City, with 1 trial reported in each city. These locations may be useful alternatives when a Salt Lake City study has restrictive eligibility or closes enrollment.

The recent trend shows monthly new-trial totals of 21 in February, 21 in March, 17 in April, 22 in May, 18 in June, and 18 in July; August currently shows four openings in the available trend. As new studies continue to appear, local patients and healthy volunteers should monitor University of Utah-affiliated sites and contact study teams early in the enrollment process.